Detailed Information

Clinical and economic burden of bacteremia due to multidrug-resistant organisms in Korea: a prospective case control study

Cited 8 time in Web of Science Cited 10 time in Scopus

Song, Kyoung-Ho; Kim, Chung-Jong; Choi, Nam-Kyong; Ahn, Jeonghoon; Choe, Pyoeng Gyun; Park, Wan Beom; Kim, Nam Joong; Choi, Hee Jung; Bae, Ji Yun; Kim, Eu Suk; Lee, Hyunju; Park, Jeong Su; Jung, Younghee; Lee, Seung Soon; Park, Kyung-Hwa; Jung, Sook-In; Kim, Yeon-Sook; Bang, Ji-Hwan; Lee, Shinwon; Kang, Yu Min; Kwak, Yee Gyung; Kim, Hong Bin

Issue Date
Elsevier BV
Journal of Global Antimicrobial Resistance, Vol.31, pp.379-385
Objectives: The socioeconomic and clinical burden of multidrug-resistant organisms (MDRO), including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), multidrugresistant Acinetobacter baumannii (MRAB), multidrug-resistant Pseudomonas aeruginosa (MRPA), and carbapenem-resistant Enterobacteriaceae (CRE) have not yet been adequately addressed.Methods: We prospectively searched for MDRO bacteremia cases with matched controls from 10 hospitals across Korea during a 6-month period in 2017. Patients were classified into the MDRO, susceptible organism, and no-infection groups. The corresponding susceptible or no-infection controls had been selected according to predefined criteria. We collected clinical information and estimated the total additional medical cost due to MDRO infections using the multistate model.Results: During the 6-month period, a total of 486 MDRO bacteremia cases (260, 87, 18, 20, and 101 cases of MRSA, MRAB, MRPA, CRE, and VRE, respectively) were identified. The 90-d mortality rates were 30.4%, 63.2%, 16.7%, 55.0%, and 47.5%, respectively. The additional costs caused by bacteremia were $15 76 8, $35 6 82, $39 908, $72 051, and $33 662 per MDRO type, respectively. Based on these 6-month data, the estimated annual number of bacteremia cases due to these five MDRO in Korea were 7979 (4070, 1396, 218, 461, and 1834 cases, respectively). Overall, this caused an estimated 3280 (1237, 882, 36, 254, and 871, respectively) deaths and cost $294 505 002 ($84 707 359, $74 387 364, $10 344 370, $45 850 215, and $79 215 694, respectively) (range $170,627,020-$416,094,679) in socioeconomic loss.Conclusions: A tremendous clinical and economic burden is caused by MDRO bacteremia compared with antibiotic-susceptible and no-infection groups. Substantial investment and efforts by related government agencies and medical staffs are needed.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial ( )
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Related Researcher

  • College of Medicine
  • Department of Medicine
Research Area Immunology, Infectious Diseases, Vaccination, 감염병, 바이러스질환, 예방접종


Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.